Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trial
Molecular Therapy · 2025-06 · 33 (6) · 2753-2767
DOI: 10.1016/j.ymthe.2024.09.006 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Molecular Therapy, 2025-06. Verfasst von Liping Zhao und 23 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Antigens, CD7, T-Lymphocytes. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Tianjin Municipality, CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)-T cell therapy showed preliminary activity in patients with refractory or relapsed T cell acute lymphoblastic leukemia (r/r T-ALL). However, many obstacles remain, including manufacturing difficulties and risk of infections. This phase I study (NCT04840875) evaluated autologous CD7 CAR-T cells manufactured without pre-selection of healthy T cells in r/r T-ALL. Thirty patients (29 children and one adult) with a median of two lines of prior therapy but without detectable peripheral leukemia were enrolled. Excluding three cases of manufacturing failures, a total of 27 (90%) patients received infusions after products were confirmed free of leukemia contamination, including 16 (59%) meeting planned target doses. Common adverse events within 30 days included grade 3-4 cytopenias (100%), grade 1-2 (70%) and 3-4 (7%, including one dose-limiting toxicity) cytokine release syndrome, grade 1 neurotoxicity (7%), grade 2 infection (4%), and grade 2 graft-versus-host disease (4%). Two patients developed grade 2 infections after day 30. At day 30, 96% responded and 85% achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi). Seventy-four percent underwent transplantation. Twelve-month progression-free survival with and without censoring transplantation was 22% (95% confidence interval 4%-100%) and 57% (41%-81%), respectively. These results support that autologous CD7 CAR-T therapy without T cell pre-selection is feasible in patients with r/r T-ALL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
- Cytology Laboratory, Beijing GoBroad Boren Hospital, Beijing 100070, China.
- Department of Hematology, Key Laboratory of Experimental Hematology, Boren Clinical Translational Center, Beijing Gobroad Boren Hospital, Beijing 100070, China.
- Shanghai YaKe Biotechnology Ltd., Shanghai 200438, China.
- Medical Laboratory, Beijing GoBroad Boren Hospital, Beijing 100070, China.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Austin, TX 77030, USA.
Förderung
- National Key Research and Development Program of China
- Natural Science Foundation of Tianjin Municipality
- CAMS Innovation Fund for Medical Sciences
- National Natural Science Foundation of China
Zitieren
APA
Zhao, L., Li, C., Zuo, S., Han, Y., Deng, B., Ling, Z., Zhang, Y., Peng, S., Xu, J., Duan, J., Wang, Z., Yu, X., Zheng, Q., Xu, X., Yuan, Y., Tian, Z., Tang, K., Zhang, Y., Niu, Q., …, & Pan, J. (2025). Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trial. Molecular Therapy, 33(6), 2753-2767. https://doi.org/10.1016/j.ymthe.2024.09.006
Vancouver
Zhao L, Li C, Zuo S, Han Y, Deng B, Ling Z, et al. Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trial. Molecular Therapy. 2025;33(6):2753-2767. doi:10.1016/j.ymthe.2024.09.006
BibTeX
@article{Zhao2025,
author = {Zhao, Liping and Li, Chuo and Zuo, Shiyu and Han, Yajing and Deng, Biping and Ling, Zhuojun and Zhang, Yanlei and Peng, Shuixiu and Xu, Jinlong and Duan, Jiajia and Wang, Zelin and Yu, Xinjian and Zheng, Qinlong and Xu, Xiuwen and Yuan, Ying and Tian, Zhenglong and Tang, Kaiting and Zhang, Yibing and Niu, Qing and Zhang, Jiecheng and Chang, Alex H and Luo, Yuechen and Feng, Xiaoming and Pan, Jing},
title = {Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trial},
journal = {Molecular Therapy},
year = {2025},
volume = {33},
number = {6},
pages = {2753--2767},
doi = {10.1016/j.ymthe.2024.09.006}
}
EUVIMED